000			01538 a2200409 4500
005			20250513102442.0
264		0	_c19970121
008			199701s 0 0 eng d
022			_a0114-5916
024	7		_a10.2165/00002018-199615010-00003 _2doi
040			_aNLM _beng _cNLM
100	1		_aHackelsberger, A
245	0	0	_aA risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection. _h[electronic resource]
260			_bDrug safety _cJul 1996
300			_a30-52 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAmoxicillin _xadministration & dosage
650	0	4	_aAnti-Bacterial Agents _xtherapeutic use
650	0	4	_aBismuth _xtherapeutic use
650	0	4	_aClarithromycin _xadministration & dosage
650	0	4	_aDrug Therapy, Combination
650	0	4	_aDyspepsia _xmicrobiology
650	0	4	_aHelicobacter Infections _xdrug therapy
650	0	4	_aHelicobacter pylori _xdrug effects
650	0	4	_aHistamine H2 Antagonists _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aNitroimidazoles _xtherapeutic use
650	0	4	_aOmeprazole _xadministration & dosage
650	0	4	_aPenicillins _xtherapeutic use
650	0	4	_aPeptic Ulcer _xmicrobiology
650	0	4	_aProton Pump Inhibitors
650	0	4	_aRisk Assessment
650	0	4	_aTetracyclines _xtherapeutic use
700	1		_aMalfertheiner, P
773	0		_tDrug safety _gvol. 15 _gno. 1 _gp. 30-52
856	4	0	_uhttps://doi.org/10.2165/00002018-199615010-00003 _zAvailable from publisher's website
999			_c8855775 _d8855775